Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-4 (of 4 Records) |
Query Trace: Fischer MA[original query] |
---|
Epidemiology and diagnosis of health care-associated infections in the NICU
Polin RA , Denson S , Brady MT , Papile LA , Baley JE , Carlo WA , Cummings JJ , Kumar P , Tan RC , Watterberg KL , Barfield WD , Jefferies AL , Macones GA , Mainous RO , Raju TNK , Wang KS , Couto J , Byington CL , Davies HD , Edwards KM , Glode MP , Jackson MA , Keyserling HL , Maldonado YA , Murray DL , Orenstein WA , Schutze GE , Willoughby RE , Zaoutis TE , Fischer MA , Gellin B , Gorman RL , Lee L , Pratt RD , Read JS , Robinson J , Safadi MAP , Seward J , Starke JR , Simon G , Tan TQ , Baker CJ , Bernstein HH , Kimberlin DW , Long SS , Meissner HC , Pickering LK , Rubin LG , Frantz J . Pediatrics 2012 129 (4) e1104-e1109 Health care-associated infections in the NICU are a major clinical problem resulting in increased morbidity and mortality, prolonged length of hospital stays, and increased medical costs. Neonates are at high risk for health care-associated infections because of impaired host defense mechanisms, limited amounts of protective endogenous flora on skin and mucosal surfaces at time of birth, reduced barrier function of neonatal skin, the use of invasive procedures and devices, and frequent exposure to broad-spectrum antibiotics. This statement will review the epidemiology and diagnosis of health care-associated infections in newborn infants. (Copyright 2012 by the American Academy of Pediatrics.) |
Policy statement--Recommended childhood and adolescent immunization schedules--United States, 2010
Bocchini JA Jr , Bradley JS , Brady MT , Bernstein HH , Byington CL , Fisher MC , Glode MP , Jackson MA , Keyserling HL , Kimberlin DW , Orenstein WA , Schutze GE , Willoughby RE Jr , Bell BP , Bortolussi R , Clover RD , Fischer MA , Gorman RL , Lee L , Pratt RD , Read JS , Gellin BG , Starke JR , Swanson J , Meissner HC , Rubin LG , Pickering LK , Baker CJ , Long SS , Frantz J , Committee on Infectious Diseases . Pediatrics 2010 125 (1) 195-6 The 2010 recommended childhood and adolescent immunization schedules have been approved by the American Academy of Pediatrics, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention, and the American Academy of Family Physicians. There are 3 schedules: one for children 0 through 6 years of age, one for people 7 through 18 years of age, and a catch-up immunization schedule for children and adolescents who start late or fall behind. These schedules reflect current recommendations for the use of vaccines licensed by the US Food and Drug Administration and include the following changes from last year: | Reference to the recommendations of the Advisory Committee on Immunization Practices for use of influenza A (H1N1) 2009 monovalent vaccine1 is included in a footnote. | Revaccination with meningococcal conjugate vaccine (MCV4) is recommended for children who remain at increased risk for meningococcal disease. A dose of MCV4 should be administered after 3 years in children who received the initial MCV4 dose at ages 2 through 6 years and after 5 years if the first dose was given at age 7 years or older. Additional doses of MCV4 are then given every 5 years.2 | Recommendations on use of combination vaccines have been updated (the use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines). The final dose in the inactivated poliovirus vaccine series should be administered on or after the 4th birthday and at least 6 months following the previous dose. If 4 doses are administered before age 4 years, an additional (fifth) dose should be administered at age 4 through 6 years.3 | Recommendations for use of the recently licensed bivalent human papillomavirus vaccine in females and the quadrivalent human papillomavirus vaccine in males are included. | Most of the footnotes for the individual vaccines have been revised to provide additional information and to clarify recommendations provided in the schedules. |
From the American Academy of Pediatrics: policy statements--modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
Bocchini Jr JA , Bernstein HH , Bradley JS , Brady MT , Byington CL , Fisher MC , Glode MP , Jackson MA , Keyserling HL , Kimberlin DW , Orenstein WA , Schutze GE , Willoughby RE , Bell B , Bortolussi R , Clover RD , Fischer MA , Gellin B , Gorman RL , Pratt RD , Lee L , Read JS , Starke JR , Swanson J , Committee on Infectious Diseases . Pediatrics 2009 124 (6) 1694-701 Palivizumab was licensed in June 1998 by the US Food and Drug Administration for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients who are at increased risk of severe disease. Safety and efficacy have been established for infants born at or before 35 weeks' gestation with or without chronic lung disease of prematurity and for infants and children with hemodynamically significant heart disease. The American Academy of Pediatrics (AAP) published a policy statement on the use of palivizumab in November 1998 (American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 1998;102[5]:1211-1216) and revised it in December 2003 (American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003;112[6 pt 1]:1442-1446), and an AAP technical report on palivizumab was published in 2003 (Meissner HC, Long SS; American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003;112[6 pt 1]:1447-1452). On the basis of the availability of additional data regarding seasonality of RSV disease as well as the limitations in available data on risk factors for identifying children who are at increased risk of serious RSV lower respiratory tract disease, AAP recommendations for immunoprophylaxis have been updated in an effort to ensure optimal balance of benefit and cost from this expensive intervention. This statement updates and replaces the 2003 AAP statement and the 2006 Red Book and is consistent with the 2009 Red Book recommendations. |
Policy statement--recommendations for the prevention and treatment of influenza in children, 2009 -2010
Committee on Infectious Diseases , Bell B , Fischer MA . Pediatrics 2009 124 (4) 1216-26 The purpose of this statement is to update current recommendations for routine use of trivalent seasonal influenza vaccine and antiviral medications for the prevention and treatment of influenza in children. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure